Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials
P.M. Burger(University Medical Center Utrecht), Frank L.J. Visseren(University Medical Center Utrecht), Jannick A N Dorresteijn(Utrecht University), Joris Holtrop(University Medical Center Utrecht), J. Wouter Jukema(Leiden University Medical Center), Stefan Koudstaal, John J.P. Kastelein(QRx Pharma (United States)), Paul M. Ridker(Herlev Hospital), Arend Mosterd(Werkgroep Cardiologische centra Nederland)
Cited by 36
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2021|6.1k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease
|New England Journal of Medicine|1996|2.4k